From bench to bedside: novel mechanisms and therapeutic advances through the development of selective peroxisome proliferator-activated receptor gamma modulators

The American Journal of Clinical Nutrition
George L Blackburn

Abstract

Type 2 diabetes is a complex disease that requires long-term therapy aimed at multiple targets. At Experimental Biology 2009 (www.eb2009.org), held last April in New Orleans, LA, the American Society for Nutrition hosted the symposium "From bench to bedside: novel therapeutic advances through the development of selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulators." Presenters addressed the latest science on novel pathways that regulate metabolism and insulin resistance, including fibroblast growth factor 21 (FGF21) and adiponectin, as well as advances in our understanding of the biology of PPARgamma, including modes of action and recently discovered side effects of PPARgamma agonists. They also explored the pharmacologic and physiologic actions of FGF21 and adiponectin, metabolic regulators that could provide novel therapeutic opportunities in the future, as well as current data on selective PPARgamma modulators. These molecules offer a new direction in the search for more specific PPARgamma activators that will retain efficacy for the treatment of diabetes without major side effects.

References

Aug 15, 2001·The Journal of Clinical Endocrinology and Metabolism·W S YangL M Chuang
Jan 27, 2007·Current Diabetes Reports·Aoife M Brennan, Christos S Mantzoros
Sep 13, 2007·JAMA : the Journal of the American Medical Association·A Michael LincoffSteven E Nissen
Sep 13, 2007·JAMA : the Journal of the American Medical Association·Sonal SinghCurt D Furberg
May 20, 2009·Journal of Molecular Biology·Alykhan MotaniYang Li
Jun 12, 2009·Lancet·Bernard Charbonnel
Jun 18, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Michael BodmerChristoph R Meier
Jun 18, 2009·Current Diabetes Reviews·Christina-Maria Kastorini, Demosthenes B Panagiotakos
Jun 18, 2009·Current Diabetes Reviews·Daniel Cuevas-RamosFrancisco J Gomez-Perez

❮ Previous
Next ❯

Citations

Aug 19, 2010·Hybridoma·Liping YaoDaiming Fan
Jun 30, 2010·Current Opinion in Endocrinology, Diabetes, and Obesity·Anna C Belkina, Gerald V Denis
Nov 13, 2009·The American Journal of Clinical Nutrition·Steven A Kliewer, David J Mangelsdorf
Nov 13, 2009·The American Journal of Clinical Nutrition·Florencia Ziemke, Christos S Mantzoros
Jun 7, 2014·Biochimica Et Biophysica Acta·Luc RochetteCatherine Vergely
Oct 27, 2015·Frontiers in Endocrinology·Yannick JeansonLouis Casteilla
May 4, 2017·Current Opinion in Lipidology·Niki KatsikiDimitri P Mikhailidis
Jun 9, 2016·Journal of Pediatric Endocrinology & Metabolism : JPEM·Renata StawerskaAndrzej Lewiński
Nov 20, 2009·The American Journal of Clinical Nutrition·Wayman Wendell Cheatham
Nov 13, 2009·The American Journal of Clinical Nutrition·Linda Slanec Higgins, Alex M Depaoli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

© 2022 Meta ULC. All rights reserved